Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo - Karjalainen, Marjo J.; Neuvonen, Pertti J.; Backman, Janne T. (European journal of clinical pharmacology, 2008)
Keywords: Adult; Area Under Curve; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Caffeine; Caffeine - pharmacokinetics; Celecoxib; Clonidine - analogs & derivatives; Clonidine - pharmacokinetics; Clonidine - pharmacology; Cross-Over Studies; Cyclooxygenase 2 Inhibitors - pharmacology; Cytochrome P-450 CYP1A2 Inhibitors; Drug Interactions; Female; Half-Life; Humans; In Vitro Techniques; Male; Medical sciences; Metabolism; Microsomes, Liver - drug effects; Microsomes, Liver - metabolism; Nonsteroidal anti-inflammatory drugs; Pharmacokinetics and Disposition; Pharmacology; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pyrazoles - pharmacology; Sulfonamides - pharmacology; Tizanidine; Celecoxib; Interaction; CYP1A2; Prediction; Caffeine; Human; Prostaglandin-endoperoxide synthase; CNS stimulant; Enzyme; Psychotropic; Isozyme; Muscle relaxant; Cytochrome P450; Enzyme inhibitor; Caffeine; Celecoxib· CYP1A2; Cyclooxygenase 2 inhibitor; In vitro; Respiratory analeptic; Non steroidal antiinflammatory agent; In vivo; Cytochrome P450 1A2; Xanthine derivatives; Oxidoreductases; Predictive factor